Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.54 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617042 | 1.00 | DGAT1 (0.54) | DGAT1SOAT1MEN1NPC1RAB9A | |
| SCHEMBL13664084 | 1.00 | DGAT1 (0.54) | DGAT1SOAT1MEN1NPC1RAB9A | |
| SCHEMBL180688 | 1.00 | DGAT1 (0.54) | DGAT1SOAT1MEN1NPC1RAB9A | |
| SCHEMBL181294 | 0.81 | DGAT1 (0.58) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL180912 | 0.81 | DGAT1 (0.62) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13664085 | 0.81 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL16549571 | 0.81 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14642922 | 0.81 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30385270 | 0.81 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL181096 | 0.81 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SOAT1 4/4885MEN1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.